Identification of candidate biomarker proteins released by human endometrial and cervical cancer cells using two-dimensional liquid chromatography/tandem mass spectrometry

Journal of Proteome Research

Volumn 6, Issue 7, 2007, Pages 2615-2622

  Li, Hongyan ^a   DeSouza, Leroi V ^a   Ghanny, Shaun ^a   Li, Wei ^a   Romaschin, Alexander D ^b,c   Colgan, Terence J ^c,d   Siu, K W Michael ^a  

^a YORK UNIVERSITY   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Candidate biomarkers; Cell released proteins; Endometrial cancer; Two dimensional liquid chromatography tandem mass spectrometry

Indexed keywords

ALPHA 1 ANTITRYPSIN; CALCIUM BINDING PROTEIN; CALGIZZARIN; CELL PROTEIN; CHAPERONIN; CLUSTERIN; CYSTATIN B; CYSTATIN C; KALLIKREIN 10; KALLIKREIN 6; MACROPHAGE MIGRATION INHIBITION FACTOR; MESOTHELIN; OSTEONECTIN; OSTEOPONTIN; POLO LIKE KINASE; PROSTATE DIFFERENTIATION FACTOR; PROTEIN WAP; PYRUVATE KINASE; RETICULON 4; SOMATOMEDIN BINDING PROTEIN 10; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN BINDING PROTEIN 7; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; ENDOMETRIUM CANCER; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; TANDEM MASS SPECTROMETRY; UTERINE CERVIX CANCER;

CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NEOPLASM PROTEINS; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 34547222017     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr0700798     Document Type: Article

References (76)

1. Arribas, J.; Borroto, A. Protein ectodomain shedding. Chem. Rev. 2002, 102, 4627-4637.
2. Blobel, C. P. Remarkable roles of proteolysis on and beyond the cell surface. Curr. Opin. Cell Biol. 2000, 12, 606-612.
3. Sahin, U.; Weskamp, G.; Kelly, K.; Zhou, H. M.; Higashiyama, S.; Peschon, J.; Hartmann, D.; Saftig, P.; Blobel, C. P. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J. Cell Biol. 2004, 164, 769-779.
4. Rose, A. A.; Siegel, P. M. Breast cancer-derived factors facilitate osteolytic bone metastasis. Bull. Cancer 2006, 93, 931-943.
5. Black, R. A. Tumor necrosis factor-alpha converting enzyme. Int. J Biochem. Cell Biol. 2002, 34, 1-5.
6. Mohamed, M. M.; Sloane, B. F. Cysteine cathepsins: multifunctional enzymes in cancer. Nat. Rev. Cancer 2006, 6, 764-775.
7. Daniel, K. G.; Kuhn, D. J.; Kazi, A.; Dou, Q. P. Anti-angiogenic and anti-tumor properties of proteasome inhibitors. Curr. Cancer Drug Targets. 2005, 5, 529-541.
8. Smalley, D. M.; Ley, K. L-selectin: mechanisms and physiological significance of ectodomain cleavage. J. Cell. Mol. Med. 2005, 9, 255-266.
9. Katayama, M.; Sekiguchi, K. Laminin-5 in epithelial tumour invasion. J. Mol. Histol.2004, 35, 277-286.
10. Nelson, C. M.; Bissell, M. J. Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. Ann. Rev. Cell Dev. Biol. 2006, 22, 287-309.
11. Ariztia, E. V.; Lee, C. J.; Gogoi, R.; Fishman, D. A. The tumor microenvironment: key to early detection. Crit. Rev. Clin. Lab. Sci. 2006, 43, 393-425.
12. Littlepage, L. E.; Egeblad, M.; Werb, Z. Coevolution of cancer and stromal cellular responses. Cancer Cell 2005, 7, 499-500.
13. Nishi, E.; Klagsbrun, M. Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a mediator of multiple physiological and pathological pathways. Growth Factors 2004, 22, 253-260.
14. Bauskin, A. R.; Brown, D. A.; Kuffner, T.; Johnen, H.; Luo, X. W.; Hunter, M.; Breit, S. N. Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res. 2006, 66, 4983-4986.
15. Chirco, R.; Liu, X. W.; Jung, K. K.; Kim, H. R. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev. 2006, 25, 99-113.
16. Giles, R.; Loberg, R. D. Can we target the chemokine network for cancer therapeutics? Curr. Cancer Drug Targets 2006, 6, 659-670.
17. Karazanashvili, G.; Abrahamsson, P. A. Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer. J Urol. 2003, 169, 445-457.
18. DeSouza, L.; Diehl, G.; Rodrigues, M. J.; Guo, J.; Romaschin, A. D.; Colgan, T. J.; Siu, K. W. M. Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. J. Proteome Res. 2005, 4, 377-386.
19. DeSouza, L. V.; Grigull, J.; Ghanny, S.; Dubé, V.; Romaschin, A. D.; Colgan, T. J.; Siu, K. W. M. Endometrial carcinoma biomarker discovery and verification using differentially tagged clinical samples with multidimensional liquid chromatography and tandem mass spectrometry. Mol. Cell. Proteomics 2007. [Online early access]. Published online: March 19, 2007.
20. Dube, V.; Grigull, J.; DeSouza, L. V.; Colgan, T. J.; Romaschin, A. D.; Siu, K. W. M. Verification of endometrial tissue biomarkers previously discovered using mass-tagging and multidimensional liquid chromatography/tandem mass spectrometry by means of immunohistochemistry in a tissue microarray format. J. Proteome Res. 2007, in press.
21. Tirumalai, R. S.; Chan, K. C.; Prieto, D. A.; Issaq, H. J.; Conrads, T. P.; Veenstra, T. D. Characterization of the low molecular weight human serum proteome. Mol. Cell. Proteomics. 2003, 2, 1096-1103.
22. Bendtsen, J. D.; Nielsen, H.; von Heijne, G.; Brunak, S. Improved prediction of signal peptides: SignalP 3.0. J. Mol. Biol. 2004, 340, 783-795.
23. Bendtsen, J. D.; Jensen, L. J.; Blom, N.; von Heijne, G.; Brunak, S. Feature-based prediction of non-classical and leaderless protein secretion. Protein Eng. Des. Sel. 2004, 17, 349-356.
24. Ashburner, M.; Ball, C. A.; Blake, J. A.; Botstein, D.; Butler, H.; Cherry, J. M.; Davis, A. P.; Dolinski, K.; Dwight, S. S.; Eppig, J. T.; Harris, M. A.; Hill, D. P.; Issel-Tarver, L.; Kasarskis, A.; Lewis, S.; Matese, J. C.; Richardson, J. E.; Ringwald, M.; Rubin, G. M.; Sherlock, G. Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat. Genet. 2000, 25, 25-29.
25. Chan, X. C. Y.; McDermott, J. C.; Siu, K. W. M. Identification of secreted proteins during skeletal muscle development. J. Proteome Res. 2007, 6, 698-710.
26. Zvonic, S.; Lefevre, M.; Kilroy, G.; Floyd, Z. E.; Delany, J. P.; Kheterpal, I.; Gravois, A.; Dow, R.; White, A.; Wu, X.; Gimble, J. M. Secretome of primary cultures of human adipose-derived stem cells: modulation of serpins by adipogenesis. Mol. Cell. Proteomics 2007, 6, 18-28.
27. Mbeunkui, F.; Fodstad, O.; Pannell, L. K. Secretory protein enrichment and analysis: an optimized approach applied on cancer cell lines using 2D LC-MS/MS. J. Proteome Res. 2006, 5, 899-906.
28. Sardana, G.; Marshall, J.; Diamandis, E. P. Discovery of candidate tumor markers for prostate cancer via proteomic analysis of cell culture-conditioned medium. Clin. Chem. 2007, 53, 429-437.
29. Anderson, N. L.; Anderson, N. G. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1, 845-867.
30. Shen, Y.; Jacobs, J. M.; Camp, D. G., 2nd; Fang, R.; Moore, R. J.; Smith, R. D.; Xiao, W.; Davis, R. W.; Tompkins, R. G. Ultra-high-efficiency strong cation exchange LC/RPLC/MS/MS for high dynamic range characterization of the human plasma proteome. Anal. Chem. 2004, 76, 1134-1144.
31. Shen, Y.; Kim, J.; Strittmatter, E. F.; Jacobs, J. M.; Camp, D. G., II; Fang, R.; Tolie, N.; Moore, R. J.; Smith, R. D. Characterization of the human blood plasma proteome. Proteomics 2005, 5, 4034-4045.
32. Omenn, G. S.; States, D. J.; Adamski, M.; Blackwell, T. W.; Menon, R.; Hermjakob, H.; Apweiler, R.; Haab, B. B.; Simpson, R. J.; Eddes, J. S.; Kapp, E. A.; Moritz, R. L.; Chan, D. W.; Rai, A. J.; Admon, A.; Aebersold, R.; Eng, J.; Hancock, W. S.; Hefta, S. A.; Meyer, H.; Paik, Y. K.; Yoo, J. S.; Ping, P.; Pounds, J.; Adkins, J.; Qian, X.; Wang, R.; Wasinger, V.; Wu, C. Y.; Zhao, X.; Zeng, R.; Archakov, A.; Tsugita, A.; Beer, I.; Pandey, A.; Pisano, M.; Andrews, P.; Tammen, H.; Speicher, D. W.; Hanash, S. M. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005, 5, 3226-3245.
33. Adkins, J. N.; Varnum, S. M.; Auberry, K. J.; Moore, R. J.; Angell, N. H.; Smith, R. D.; Springer, D. L.; Pounds, J. G. Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Mol. Cell. Proteomics 2002, 1, 947-955.
34. Marshall, J.; Jankowski, A.; Furesz, S.; Kireeva, I.; Barker, L.; Dombrovsky, M.; Zhu, W.; Jacks, K.; Ingratta, L.; Bruin, J.; Kristensen, E.; Zhang, R.; Stanton, E.; Takahashi, M.; Jackowski, G. Human serum proteins preseparated by electrophoresis or chromatography followed by tandem mass spectrometry. J. Proteome Res. 2004, 3, 364-382.
35. Yang, E. C. C.; Guo, J.; Diehl, G.; DeSouza, L.; Rodrigues, M. J.; Romaschin, A. D.; Colgan, T. J.; Siu, K. W. M. Expression profiling of endometrial malignancies reveals a new tumor marker: Chaperonin 10. J. Proteome Res. 2004, 3, 636-643.
36. Guo, J.; Yang, E. C. C.; DeSouza, L.; Diehl, G.; Rodrigues, M. J.; Romaschin, A. D.; Colgan, T. J.; Siu, K. W. M. A strategy for high-resolution and protein identification in surface- enhanced laser desorption/ionization (SELDI) mass spectrometry: calgranulin A and chaperonin 10 as protein markers for endometrial carcinoma. Proteomics, 2005, 5, 1953-1966.
37. Akyol, S.; Gercel-Taylor, C.; Reynolds, L. C.; Taylor, D. D. HSP-10 in ovarian cancer: expression and suppression of T-cell signaling. Gynecol. Oncol. 2006, 101, 481-486.
38. Hammond, F.; Cavanagh, A.; Morton, H.; Hillyard, N.; Papaioannou, A.; Clark, M.; Wanigesekera, D.; Swanton, M.; Ward, R. Isolation of antibodies which neutralise the activity of early pregnancy factor. J. Immunol. Methods 2000, 244, 175-184.
39. Summers, K. M.; Murphy, R. M.; Webb, G. C.; Peters, G. B.; Morton, H.; Cassady, A. I.; Cavanagh, A. C. The human early pregnancy factor/chaperonin 10 gene family. Biochem. Mol. Med. 1996, 58, 52-58.
40. Morton, H.; Hegh, V.; Clunie, G. J. A. Studies of the rosette inhibition test in pregnant mice: evidence of immunosuppression? Proc. R. Soc. B 1976, 193, 413-419.
41. Morton, H.; Rolfe, B. E.; Cavanagh, A. C. Ovum factor and early pregnancy factor. Curr. Top. Dev. Biol. 1987, 23, 73-92.
42. Raspopov, S. A.; El-Faramawy, A.; Thomson, B. A.; Siu, K. W. M. Infrared multiphoton dissociation in quadrupole time-of-flight mass spectrometry: top-down characterization of proteins. Anal. Chem. 2006, 78, 4572-4577.
43. Quinn, K. A.; Athanasis-Plastis, S.; Wong, T.-Y.; Rolfe, B. E.; Cavanagh, A. C.; Morton, H. Monoclonal antibodies to early pregnancy factor perturb tumour cell growth. Clin. Exp. Immunol. 1990, 80, 100-108.
44. Staal, G. E. J.; Rijksen, G. Pyruvate kinase in selected human tumors. In Biochemical and Molecular Aspects of Selected Cancers, Vol. 2.: Pretlow, T. G., Pretlow, T. P., Eds.; Academic Press: San Diego, CA, 1991; pp 313-337.
45. Hacker, H. J.; Steinberg, P.; Bannasch, P. Pyruvate kinase isoenzyme shift from L-type to M2-type is a late event in hepatocarcinogenesis induced in rats by a choline-deficient/dl-ethionine-supplemented diet. Carcinogenesis 1998, 19, 99-107.
46. Eigenbrodt, E.; Reinacher, M.; Scheefers-Borchel, U.; Scheefers, H.; Friis, R. R. Double role of pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. In Critical Reviews in Oncogenesis, Vol. 3.: Perucho, M., Ed.; CRC Press: Boca Raton, FL, 1992; pp 91-115.
47. Mazurek, S.; Boschek, C. B.; Eigenbrodt, E. The role of phosphometabolites in cell proliferation, energy metabolism and tumor therapy. J. Bioenerg. Biomembr. 1997, 29, 315-330.
48. Mazurek, S.; Eigenbrodt, E. The tumor metabolome. Anticancer Res. 2003, 23, 1149-1154.
49. Ashizawa, K.; Willingham, M. C.; Liang, C. M.; Cheng, S. Y. In vivo regulation of monomer-tetramer conversion of pyruvate kinase subtypeM2 by glucose is mediated by fructose-1,6-bisphosphate. J. Biol. Chem. 1991, 266, 16842-16846.
50. Schneider, J.; Neu, K.; Grimm, H.; Velcovsky, H.-G.; Wiesse, G.; Eigenbrodt, E. Tumour M2- pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring. Anticancer Res. 2002, 22, 311-318.
51. Kim, C. W.; Kim, J. I.; Park, S. H.; Han, J. Y.; Kim, J. K.; Chung, K. W.; Sun, H. S. Usefulness of plasma tumor M2-pyruvate kinase in the diagnosis of gastrointestinal cancer. Korean J. Gastroenterol. 2003, 42, 387-393.
52. Tanaka, M.; Adzuma, K.; Iwami, M.; Yoshimoto, K.; Monden, Y.; Itakura, M. Human calgizzarin; one colorectal cancer-related gene selected by a large scale random cDNA sequencing and northern blot analysis. Cancer Lett. 1995, 89, 195-200.
53. Chaurand, P.; DaGue, B. B.; Pearsall, R. S.; Threadgill, D. W.; Caprioli, R. M. Profiling proteins from azoxymethane-induced colon tumors at the molecular level by matrix-assisted laser desorption/ionization mass spectrometry. Proteomics 2001, 1, 1320-1326.
54. Sun, Z.; Yang, P. Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression. Lancet Oncol. 2004, 5, 182-190.
55. Ryu, J. W.; Kim, H. J.; Lee, Y. S.; Myong, N. H.; Hwang, C. H.; Lee, G. S.; Yom, H. C. The proteomics approach to find biomarkers in gastric cancer. J. Korean Med. Sci. 2003, 18, 505-509.
56. Ren, Y.; Tsui, H. T.; Poon, R. T.; Ng, I. O.; Li, Z.; Chen, Y.; Jiang, G.; Lau, C.; Yu, W. C.; Bacher, M.; Fan, S. T. Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int. J. Cancer 2003, 107, 22-29.
57. Campa, M. J.; Wang, M. Z.; Howard, B.; Fitzgerald, M. C.; Patz, E. F., Jr. Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. Cancer Res. 2003, 63, 1652-1656.
58. Markert, J. M.; Fuller, C. M.; Gillespie, G. Y.; Bubien, J. K.; McLean, L. A.; Hong, R. L.; Lee, K.; Gullans, S. R.; Mapstone, T. B.; Benos, D. J. Differential gene expression profiling in human brain tumors. Physiol. Genomics. 2001, 555, 21-33.
59. Bacher, M.; Schrader, J.; Thompson, N.; Kuschela, K.; Gemsa, D.; Waeber, G.; Schlegel, J. Up-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme. Am. J. Pathol. 2003, 162, 11-17.
60. Santin, A. D.; Diamandis, E. P.; Bellone, S.; Marizzoni, M.; Bandiera, E.; Palmieri, M.; Papasakelariou, C.; Katsaros, D.; Burnett, A.; Pecorelli, S. Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas. Am. J. Obstet. Gynecol. 2006, 194, 1296-1302.
61. Zhang, Y.; Bhat, I.; Zeng, M.; Jayal, G.; Wazer, D. E.; Band, H.; Band, V. Human kallikrein 10, a predictive marker for breast cancer. Biol. Chem. 2006, 387, 715-721.
62. Huang, C. Y.; Cheng, W. F.; Lee, C. N.; Su, Y. N.; Chien, S. C.; Tzeng, Y. L.; Hsieh, C. Y.; Chen, C. A. Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor. Anticancer Res. 2006, 26, 4721-4728.
63. Ho, M.; Hassan, R.; Zhang, J.; Wang, Q. C.; Onda, M.; Bera, T.; Pastan, I. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin. Cancer Res. 2005, 11, 3814-3820.
64. Osman, I.; Bajorin, D. F.; Sun, T. T.; Zhong, H.; Douglas, D.; Scattergood, J.; Zheng, R.; Han, M.; Marshall, K. W.; Liew, C. C. Novel blood biomarkers of human urinary bladder cancer. Clin. Cancer Res. 2006, 12, 3374-3380.
65. Renehan, A. G.; Harvie, M.; Howell, A. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocr. Relat. Cancer 2006, 13, 273-278.
66. Shannan, B.; Seifert, M.; Leskov, K.; Willis, J.; Boothman, D.; Tilgen, W.; Reichrath, J. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ. 2006, 13, 12-19.
67. Hellstrom, I.; Raycraft, J.; Hayden-Ledbetter, M.; Ledbetter, J. A.; Schummer, M.; McIntosh, M.; Drescher, C.; Urban, N. Hellstrom, K. E. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003, 63, 3695-3700.
68. Bouchard, D.; Morriset, D.; Bourbonnais, Y.; Tremblay, G. M. Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol. 2006, 7, 167-174.
69. Takahashi, T.; Sano, B.; Nagata, T.; Kato, H.; Sugiyama, Y.; Kunieda, K.; Kimura, M.; Okano, Y.; Saji, S. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci. 2003, 94, 148-152.
70. Weichert, W.; Kristiansen, G.; Schmidt, M.; Gekeler, V.; Noske, A.; Niesporek, S.; Dietel, M.; Denkert, C. Polo-like kinase 1 expression is a prognostic factor in human colon cancer. World J. Gastroenterol. 2005, 11, 5644-5650.
71. Watari, A.; Yutsudo, M. Multi-functional gene ASY/Nogo/RTN-X/RTN4: apoptosis, tumor suppression, and inhibition of neuronal regeneration. Apoptosis 2003, 8, 5-9.
72. El-Tanani, M. K.; Campbell, F. C.; Kurisetty, V.; Jin, D.; McCann, M.; Rudland, P. S. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev. 2006, 17, 463.
73. Kao, C. L.; Chiou, S. H.; Ho, D. M.; Chen, Y. J.; Liu, R. S.; Lo, C. W.; Tsai, F. T.; Lin, C. H.; Ku, H. H.; Yu, S. M.; Wong, T. T. Elevation of plasma and cerebrospinal fluid osteopontin levels in patients with atypical teratoid/rhabdoid tumor. Am. J. Clin. Pathol. 2005, 123, 297-304.
74. Chirco, R.; Liu, X. W.; Jung, K. K.; Kim, H. R. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev. 2006, 25, 99-113.
75. Kos, J.; Werle, B.; Lah, T.; Brunner, N. Cysteine proteinases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer. Int. J. Biol. Markers 2000, 15, 84-89.
76. Frlan, R.; Gobec, S. Inhibitors of cathepsin B. Curr. Med. Chem. 2006, 13, 2309-2327.